Manuela H.
- Country
- Germany
- Department
- Klinik Med III
Research Overview
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
- Phase 3 Multicenter Randomized Trial of Venetoclax, Obinutuzumab, and Pirtobrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Data & Insights
Has run more than one trial at 70 of 196 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), focusing on innovative therapeutic approaches for blood cancers.
- Blood Cancer Treatment
- Leukemia Management
- Lymphoma Therapy
Their expertise encompasses targeted therapies and novel treatment combinations for hematologic malignancies.
Treatment Innovation
The investigator explores fixed-duration treatment protocols and MRD-guided therapy approaches in blood cancer treatment, advancing personalized medicine strategies.
- Targeted Therapy Development
- Treatment Duration Optimization
- Combination Therapy Approaches
Their work focuses on optimizing treatment durations to enhance patient outcomes in hematologic conditions.
Clinical Advancement
The investigator evaluates progression-free survival in previously untreated patients, contributing to the development of more effective therapeutic strategies.
- Treatment Response Assessment
- Disease Progression Monitoring
- Patient Outcome Improvement
Their research aims to establish new standards in blood cancer treatment through innovative therapeutic combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.